

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/081,010	02/15/2002	Philippe Maria Clotaire Margaron	273012011800	1251
7590 09/21/2005			EXAMINER	
Kawai Lau			FAY, ZOHREH A	
Morrison & Fo	erster LLP			
Suite 500			ART UNIT	PAPER NUMBER
3811 Valley Centre Drive			1618	
San Diego, CA 92130-2332			DATE MAILED: 09/21/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	N 1					
	Application No.	Applicant(s)				
	10/081,010	MARGARON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Zohreh A. Fay	1618				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	•					
1) Responsive to communication(s) filed on	<u>.</u> .					
a) ☐ This action is FINAL . 2b) ☑ This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-32</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-26 and 29-32</u> is/are rejected.						
7) Claim(s) <u>27 and 28</u> is/are objected to.		•				
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. ☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) Notice of References Cited (PTO-892)	A) Distanciano Comerca	(PTO 413)				
2) Notice of Praftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	4) Interview Summary (PTO-413) Paper No(s)/Mail Date				
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Notice of Informal Patent Application (PTO-152) Other:				
. upor mojojiman vate	o) [_] Out					

Application/Control Number: 10/081,010

Art Unit: 1618

Claims 1-32 are presented for examination.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-26 and 29 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 98/34644.

The WO Patent teaches the use of reducing inflammation. The above reference teaches the steps of 1) bringing the injured tissues or "pre-injured tissues" with a photosensitizing agent capable of penetrating into the tissue 2) exposing the tissue to the light having wave length absorbed by photosensitizing agent for a time sufficient to reduce or prevent the inflammation. See the abstract and pages 20-28. The above reference differs from the claimed invention in reducing inflammation in tissues exposed to photodynamic therapy and the tissues that overlap with the tissues that have been treated with normal dose PDT. It would have been obvious to a person skilled in the art to use a low dose PDT for the treatment of inflammation, considering that the tissues

Application/Control Number: 10/081,010

Art Unit: 1618

overlapping with tissues subjected to photodynamic therapy are considered to be preinjured tissues, which reads on the teachings of the above reference. Furthermore, the use of normal dose photodynamic for the reduction or prevention of inflammation is taught by the above reference.

One skilled in the art would have been motivated to employ the teachings of the above reference, since it relates t the use of normal dose photodynamic therapy for the prevention or reduction of inflammation in general in injured and pre-injured tissues. To treat inflammation arising from photodynamic therapy or any other source, using low dose photodynamic therapy taught by the prior art, as an anti-inflammatory agent would have been obvious to a person skilled in the art in the absence of evidence to the contrary. Applicant has presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, claims 1-26 and 29-32 are properly rejected under 35 U.S.C. 103.

Claims 27 and 28 are objected to as being dependent on a rejected claim.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh A. Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on Monday to Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/081,010 Page 4

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Z.F

